Experimental Malaria Vaccine Foisted on Sub Saharan Nations
Last year, UNICEF awarded GSK (GlaxoSmithKline) a $170 million contract for 18 million doses of their malaria “vaccines”. In collaboration with the Gates Foundation, GSK is seeking to sell 80-100 million of these shots for sub saharan children by 2030. The clinical trials for Mosquirix, the trade name for GSK’s malaria shot, demonstrated low VE and high rates of SAEs as well as a higher case fatality rate for hospitalized vaccine recipients compared to the placebo group. WHO launched a pilot study in three countries (Malawi, Ghana and Kenya) with 720,000 randomly assigned child participants to supposedly address these concerns without the free, prior and informed consent of the participants and their parents, violating the prime standard of research ethics. Instead, WHO denied their study was a “research activity” and claimed to have the “implied consent” of the families and their children.
An implied consent process is one in which parents are informed of imminent vaccination through social mobilization and communication, sometimes including letters directly addressed to parents. Subsequently, the physical presence of the child or adolescent, with or without an accompanying parent at the vaccination session, is considered to imply consent,” said a WHO spokesperson.
“Implied consent” also means that participants are not aware they are participants in a study and thus do not understand the risks associated with participating in the study. Particularly, the 2x higher risk of death after vaccination for females. As usual, WHO continued the big pharma tradition of using sub Saharans as human guinea pigs.
A BMJ reanalysis of the clinical trials demonstrated that the malaria vaccine, designed to target the parasites asexual reproduction in the liver, was only 36% effective against infections, after four shots, and came with a 10x higher risk of developing meningitis, a 2x higher risk of cerebral malaria and a higher rate of death for vaccine recipients hospitalized with severe malaria (3.24%) compared to the placebo group (1.55%). Female vaccine recipients had a 33% higher all-cause mortality rate than both males and females in the placebo group. Excess mortality among vaccine recipients increased after the booster dose. Additionally, VE dropped to 2.5% in year four and became negative after five resulting in a rebound malaria.
Despite the existence of efficacious anti-parasite treatments such as Ivermectin and an obvious culprit for higher rates of mosquito borne diseases (i.e. poor drainage and sanitation infrastructure and a scarcity of clean drinking water) the WHO continues to push the dubious GSK malaria vaccine on sub Saharan Africa. Just replacing the open latrine system common in poor rural areas and even cities there with piped water and flushable toilets significantly reduces the prevalence rate of malaria which is positively correlated with poverty which is a proxy for access to clean drinking water. Of course, reducing poverty and improving drinking water and sanitation systems is not a quick fix that will immediately return profit to shareholders.
Even Gates funded researchers recognize the efficacy of Ivermectin for parasitic diseases such as Malaria.
Originally posted on Quora July 13, 2023